text_1: Therapeutics receiving accelerated approval encounter a lower frequency of post-marketing safety events
text_2: Main Outcomes and Measures A composite of (1) withdrawals due to safety concerns, (2) FDA issuance of incremental boxed warnings added in the postmarket period, and (3) FDA issuance of safety communications.